Drug intelligence / Profile preview

terazosin

Development stage: Approved
Lead developer: Abbott
Modality: Small Molecules
Administration: Oral

Overview

Terazosin is an alpha-1 adrenergic antagonist (alpha-blocker) used primarily to treat benign prostatic hyperplasia (BPH) and hypertension. It works by selectively blocking alpha-1 adrenergic receptors, leading to relaxation of smooth muscle in blood vessels and the prostate. This action lowers blood pressure and improves urinary flow in patients with BPH. Terazosin is a quinazoline derivative available as oral capsules or solution. The drug was originally marketed under the brand name Hytrin (now discontinued in the US), but generic versions and other brands such as Tezruly are available[1][2][4][5].

Brand names: HytrinTezruly
Other names: terazosin hydrochloride

Targets

ADRA1A (α1A)KCNH2 (Voltage-gated potassium channel subfamily H member 2)

Beyond the preview

Go deeper on terazosin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on terazosin.

Explore the full profile